Roger Franklin
Partner @ Hadean Ventures
Roger Franklin is a Series A investor at Hadean Ventures focused on Health Care and Medical. Roger has wide ranging experience in the business of life science spanning over a decade across the strategy consulting, investment banking and venture capital industries. Prior to his business career, Roger completed his academic training in biochemistry at Oxford University before specialising in oncology during his doctoral work at Cambridge’sLaboratory of Molecular Biology (LMB).Most recently, Roger was senior pharmaceutical and biotechnology analyst at Liberum, an investment bank in London during which time his recommendations delivered top quartile performance. He also has extensive public market experience including IPOs and secondary fundraises. Prior to Liberum, Roger worked for a major European life science venture firm including responsibility for deal sourcing and due diligence as well as sitting on the boards of multiple portfolio companies.At Hadean, Roger is based in the Stockholm office and is particularly focused on investments in the therapeutics space.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Roger Franklin invests in
Stages Roger Franklin invests in
Countries Roger Franklin invests in
Investment Focus
Industry
- Health Care 3 (50%)
- Medical 2 (33%)
- Biotechnology 2 (33%)
- Fitness 1 (17%)
- Wellness 1 (17%)
Stage
- Series A 3 (50%)
- Series B 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- Norway 1 (17%)
- Sweden 1 (17%)
- Germany 1 (17%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $4.5M / Series B / Jul 22, 2025 | |
Actithera
|
Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M / Series A / Jul 09, 2025 | |
|
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $27.6M / Series B / Jan 20, 2025 | |
Complement Therapeutics
|
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies. | $78.7M / Series A / Apr 17, 2023 | |
Emergence Therapeutics
|
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as anADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need. | $98.1M / Series A / Dec 07, 2021 | |
|
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $20.5M / Venture - Series Unknown / Jul 07, 2020 |
Co-Investors
About Hadean Ventures
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Hadean Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Florian Eckhardt
Senior Investment Director
|
|||
Ingrid Akay
Founder and Managing Partner
|
|||
Ingrid Beyer
Head of Investor Relations
|
|||
|
Roger Franklin
Partner
|
|||
Walter Stockinger
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Roger Franklin invest in?
Roger Franklin invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Roger Franklin last invest?
The most recent investment recorded for Roger Franklin closed in Jul 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
